Filing Flows › Spero Therapeutics (SPRO) › Q1 2026 › vs Q1 2025
Spero Therapeutics (SPRO) Q1 2026 vs Q1 2025 (year over year)
Spero Therapeutics's revenue fell $5.6M (-96%) from $5.9M in Q1 2025 to $258K in Q1 2026.
Spero Therapeutics, Q1 2026: revenue $258K (-96% year over year), net loss $7.2M, operating cash flow $15.9M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $258K | $5.9M | −$5.6M | -96% |
| Other income, net | $335K | $865K | −$530K | -61% |
| Net loss | $7.2M | $13.9M | −$6.7M | -48% |
| Costs & expenses | $7.8M | $20.6M | −$12.8M | -62% |
| Operating costs | $7.8M | $20.6M | −$12.8M | -62% |
| Research & development | $2.9M | $13.6M | −$10.7M | -79% |
| General & admin | $4.9M | $6.8M | −$1.9M | -28% |
| Operating cash sources | $23.1M | $9.9M | $13.2M | +134% |
| Share-based compensation | $1.1M | $1.6M | −$442K | -28% |
| Working capital & other | $22.0M | $8.3M | $13.6M | +164% |
| Net loss absorbed | $7.2M | $13.9M | −$6.7M | -48% |
| Operating cash flow | $15.9M | −$4.0M | $19.9M | — |
Questions
How much did Spero Therapeutics's revenue grow year over year in Q1 2026?
Spero Therapeutics's revenue fell $5.6M (-96%) from $5.9M in Q1 2025 to $258K in Q1 2026.